"Never doubt that a small group of thoughtful, committed citizens can change the world. Indeed, it is the only thing that ever has."

Margaret Mead
Review article
peer-reviewed

Cardio-Oncology: Cancer Therapy-related Cardiovascular Complications in a Molecular Targeted Era: New Concepts and Perspectives



Abstract

Cardio-oncology is a medical discipline that identifies, prevents, and treats the cardiovascular complications related to cancer therapy. Due to the remarkable proliferation of new cancer therapies causing cardiovascular complications, such as hypertension, heart failure, vascular complications, and cardiac arrhythmia, we provide an extensive, comprehensive revision of the most up-to-date scientific information available on the cardiovascular complications associated with the use of newer, novel chemotherapeutic agents, including their reported incidence, suggested pathophysiology, clinical manifestations, potential treatment, and prevention. The authors consider this topic to be relevant for the clinicians since cardiovascular complications associated with the administration of recently approved drugs are relatively underappreciated.

The purpose of this article is to provide a state-of-the-art review of cardiovascular complications associated with the use of newer, novel chemotherapeutic agents and targeted therapies, including their reported incidence, suggested pathophysiology, clinical manifestations, potential treatment, and prevention. 

Ongoing efforts are needed to provide a better understanding of the frequency, mechanisms of disease, prevention, and treatment of cardiovascular complications induced by the newer, novel chemotherapeutic agents. Development of a cardio-oncology discipline is warranted in order to promote task forces aimed at the creation of oncology patient-centered guidelines for the detection, prevention, and treatment of potential cardiovascular side effects associated with newer cancer therapies.



Want to read more?

Create a free account to continue reading this article.

Already a member? Login.



Review article
peer-reviewed

Cardio-Oncology: Cancer Therapy-related Cardiovascular Complications in a Molecular Targeted Era: New Concepts and Perspectives


Author Information

David Hurtado-de-Mendoza Corresponding Author

University of Miami Miller School of Medicine, University of Miami Miller School of Medicine/Jackson Memorial Hospital, Florida, USA

Arturo Loaiza-Bonilla

Medicine, Hematology and Oncology, Cancer Treatment Centers of America

Paula A. Bonilla-Reyes

Facultad de Medicina, Pontificia Universidad Javeriana

Gabriel Tinoco

Department of Internal Medicine, The Ohio State University College of Medicine

Rodrigo Alcorta

Facultad de Medicina, Universidad Peruana Cayetano Heredia


Ethics Statement and Conflict of Interest Disclosures

Conflicts of interest: The authors have declared that no conflicts of interest exist.

Acknowledgements

We would like to thank Eng. Patricio Pasco for his invaluable help with digitalization of the figures presented in this Review Article.


Review article
peer-reviewed

Cardio-Oncology: Cancer Therapy-related Cardiovascular Complications in a Molecular Targeted Era: New Concepts and Perspectives


Figures etc.

Share
Review article
peer-reviewed

Cardio-Oncology: Cancer Therapy-related Cardiovascular Complications in a Molecular Targeted Era: New Concepts and Perspectives

  • Author Information
    David Hurtado-de-Mendoza Corresponding Author

    University of Miami Miller School of Medicine, University of Miami Miller School of Medicine/Jackson Memorial Hospital, Florida, USA

    Arturo Loaiza-Bonilla

    Medicine, Hematology and Oncology, Cancer Treatment Centers of America

    Paula A. Bonilla-Reyes

    Facultad de Medicina, Pontificia Universidad Javeriana

    Gabriel Tinoco

    Department of Internal Medicine, The Ohio State University College of Medicine

    Rodrigo Alcorta

    Facultad de Medicina, Universidad Peruana Cayetano Heredia


    Ethics Statement and Conflict of Interest Disclosures

    Conflicts of interest: The authors have declared that no conflicts of interest exist.

    Acknowledgements

    We would like to thank Eng. Patricio Pasco for his invaluable help with digitalization of the figures presented in this Review Article.


    Article Information

    Published: May 18, 2017

    DOI

    10.7759/cureus.1258

    Cite this article as:

    Hurtado-de-mendoza D, Loaiza-bonilla A, Bonilla-reyes P A, et al. (May 18, 2017) Cardio-Oncology: Cancer Therapy-related Cardiovascular Complications in a Molecular Targeted Era: New Concepts and Perspectives. Cureus 9(5): e1258. doi:10.7759/cureus.1258

    Publication history

    Received by Cureus: September 14, 2016
    Peer review began: February 08, 2017
    Peer review concluded: May 09, 2017
    Published: May 18, 2017

    Copyright

    © Copyright 2017
    Hurtado-de-Mendoza et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 3.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

    License

    This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Cardio-oncology is a medical discipline that identifies, prevents, and treats the cardiovascular complications related to cancer therapy. Due to the remarkable proliferation of new cancer therapies causing cardiovascular complications, such as hypertension, heart failure, vascular complications, and cardiac arrhythmia, we provide an extensive, comprehensive revision of the most up-to-date scientific information available on the cardiovascular complications associated with the use of newer, novel chemotherapeutic agents, including their reported incidence, suggested pathophysiology, clinical manifestations, potential treatment, and prevention. The authors consider this topic to be relevant for the clinicians since cardiovascular complications associated with the administration of recently approved drugs are relatively underappreciated.

The purpose of this article is to provide a state-of-the-art review of cardiovascular complications associated with the use of newer, novel chemotherapeutic agents and targeted therapies, including their reported incidence, suggested pathophysiology, clinical manifestations, potential treatment, and prevention. 

Ongoing efforts are needed to provide a better understanding of the frequency, mechanisms of disease, prevention, and treatment of cardiovascular complications induced by the newer, novel chemotherapeutic agents. Development of a cardio-oncology discipline is warranted in order to promote task forces aimed at the creation of oncology patient-centered guidelines for the detection, prevention, and treatment of potential cardiovascular side effects associated with newer cancer therapies.



Want to read more?

Create a free account to continue reading this article.

Already a member? Login.



David Hurtado-de-Mendoza, M.D.

University of Miami Miller School of Medicine, University of Miami Miller School of Medicine/Jackson Memorial Hospital, Florida, USA

For correspondence:
davidmarshall2016@gmail.com

Arturo Loaiza-Bonilla

Medicine, Hematology and Oncology, Cancer Treatment Centers of America

Paula A. Bonilla-Reyes

Facultad de Medicina, Pontificia Universidad Javeriana

Gabriel Tinoco

Department of Internal Medicine, The Ohio State University College of Medicine

Rodrigo Alcorta

Facultad de Medicina, Universidad Peruana Cayetano Heredia

David Hurtado-de-Mendoza, M.D.

University of Miami Miller School of Medicine, University of Miami Miller School of Medicine/Jackson Memorial Hospital, Florida, USA

For correspondence:
davidmarshall2016@gmail.com

Arturo Loaiza-Bonilla

Medicine, Hematology and Oncology, Cancer Treatment Centers of America

Paula A. Bonilla-Reyes

Facultad de Medicina, Pontificia Universidad Javeriana

Gabriel Tinoco

Department of Internal Medicine, The Ohio State University College of Medicine

Rodrigo Alcorta

Facultad de Medicina, Universidad Peruana Cayetano Heredia